We appreciate your patience. Your content is on the way.
SWOT Analysis
- S
- W
- O
- T
Technical Analysis
Moving Averages
We appreciate your patience. Your content is on the way.
Current Price


- Bullish Moving Averages
- Bearish Moving Averages
Resistance and support
We appreciate your patience. Your content is on the way.
Company Financials
- Profit and loss statement
- Balance sheet
- Quarterly Result
- Ratio
We appreciate your patience. Your content is on the way.
Quick Results Snapshot
We appreciate your patience. Your content is on the way.
Stocks Comparison
Table
Chart
We appreciate your patience. Your content is on the way.
Corporate Action
- Announcement
- Board Meeting
- Dividend
- Split
- Rights
- Events
Insider & Institutional Activity
- Bulk Block Deals
- Insider Trading & SAST
We appreciate your patience. Your content is on the way.
About Lincoln Pharmaceuticals Ltd
Stock PE (TTM)
Promoter Holding
Book Value
ROCE
ROE
Lincoln Pharmaceuticals Limited, promoted by Mahendra G Patel, Rajnikant G Patel and Hasmukhbhai I Patel, as a Partnership Firm in January, 1979 to manufacture pharmaceutical formulations was converted into a Public Limited Company in Jan. `95. All the assets and business of the erstwhile partnership were transferred to the Company. The Company is engaged in the business of manufacturing and trading of pharmaceutical products. The focused area includes anti-infective, respiratory system, gynecology, cardio & CNS, anti-diabetic, anti malaria, among others. The Company, incorporated in January, 1995, was carrying on its business by getting its products manufactured on loan licence basis from 1979 to 1982. It then set up its own manufacturing facilities at Naroda, Gujarat for manufacturing tablets, capsules, liquid and powder syrups and, ointments. It is also getting its products manufactured on loan licence basis from other manufacturers to meet the demand of small volume parenterals. The company has set up a modern formulation manufacturing plant at Khatraj (Mehsana district), Gujarat, to manufacture small volume parenterals like dry powder injectables, liquid vial, liquid ampoules and eye drops and expand its production capacities of the existing products. It is also in the process of establishing a fully equipped laboratory to undertake in-house testing of its products for better quality control and R&D. It came out with a public issue in Feb.`96 to part-finance its project. The Company launched Next Generation Progesterone Therapy "ProlinSpray" during the year 2018. During the year 2021-22, Lincoln Parenteral Limited, an erstwhile subsidiary, merged with the Company through Scheme of Amalgamation and Lincoln Parenteral Limited ceased to be a subsidiary of the Company. The Company acquired a plant in Mehsana, Gujarat to launch Cephalosporin products in 2022.
Lincoln Pharmaceuticals share price as on 16 May 2025 is Rs. 601.85. Over the past 6 months, the Lincoln Pharmaceuticals share price has decreased by 2.43% and in the last one year, it has increased by 2.71%. The 52-week low for Lincoln Pharmaceuticals share price was Rs. 499 and 52-week high was Rs. 979.5.
531633
LINCOLN
INE405C01035
Sep
Lincoln Pharmaceuticals Ltd FAQs
You can buy Lincoln Pharmaceuticals Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Lincoln Pharmaceuticals Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of May 15, 2025 03:43 PM the closing price of Lincoln Pharmaceuticals Ltd was Rs.601.85.
The latest PE ratio of Lincoln Pharmaceuticals Ltd as of May 15, 2025 03:43 PM is 13.20
The latest PB ratio of Lincoln Pharmaceuticals Ltd as of May 15, 2025 03:43 PM is 0.54
The 52-week high of Lincoln Pharmaceuticals Ltd share price is Rs. 979.50 while the 52-week low is Rs. 499.00
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of May 15, 2025 03:43 PM, the market cap of Lincoln Pharmaceuticals Ltd stood at Rs. 1,205.51 Cr.
Market Outlook
View allWe appreciate your patience. Your content is on the way.